FRA:4AB • US00287Y1091
4AB gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 78 industry peers in the Biotechnology industry. Both the profitability and the financial health of 4AB get a neutral evaluation. Nothing too spectacular is happening here. 4AB is cheap, but on the other hand it scores bad on growth.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROIC | 15.64% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Altman-Z | 2.43 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.49 | ||
| Fwd PE | 15.49 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.2 | ||
| EV/EBITDA | 16.34 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.04% |
FRA:4AB (2/20/2026, 7:00:00 PM)
191.2
+0.6 (+0.31%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.04% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.49 | ||
| Fwd PE | 15.49 | ||
| P/S | 6.67 | ||
| P/FCF | 20.2 | ||
| P/OCF | 19.06 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.34 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROCE | 20.86% | ||
| ROIC | 15.64% | ||
| ROICexc | 16.59% | ||
| ROICexgc | 572.43% | ||
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% | ||
| FCFM | 33% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 14.25% | ||
| Cap/Sales | 1.97% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 838.33% | ||
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z | 2.43 |
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.
ChartMill assigns a valuation rating of 7 / 10 to ABBVIE INC (4AB.DE). This can be considered as Undervalued.
ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.
The financial health rating of ABBVIE INC (4AB.DE) is 4 / 10.
The dividend rating of ABBVIE INC (4AB.DE) is 6 / 10 and the dividend payout ratio is 489.69%.